
About Caribou Biosciences
Caribou Biosciences is a publicly listed company based in Berkeley (United States) founded in 2011 by Jennifer Doudna, James Berger, and Martin Jinek. Provider of cell therapies to treat cancer and hematologic conditions. Caribou Biosciences has raised $156.55 million across 6 funding rounds from investors including AbbVie, Pfizer and Novartis. The company has 147 employees. Its website cariboubio.com draws about 10 thousand monthly visits. Caribou Biosciences offers products and services including chRDNA Technology and CAR-T Cell Therapies. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Caribou Biosciences, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Caribou Biosciences was founded in 2011 in Berkeley, United States, within the biotechnology sector. Cellular engineering and analysis solutions are developed based on CRISPR-Cas9 biology. These tools are applied across therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. CAR-T cell therapies for non-Hodgkin lymphoma and myeloid leukemia have been created, as have iPSC-derived CAR-NK therapies targeting solid tumors. Operations focus on advancing treatments for hematologic and oncologic conditions.
- Headquarters Berkeley, United States
- Employees 147
- Founders Jennifer Doudna, James Berger, Martin Jinek
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website cariboubio.com
- Social LinkedIn X
- Legal Name Caribou Biosciences, Inc.
- Annual Revenue$11.16 M (USD)11.66as on Dec 31, 2025
- Net Profit-$148.13 M (USD)0.66as on Dec 31, 2025
- EBITDA-$132.55 M (USD)18.53as on Dec 31, 2025
- Total Equity Funding$156.55M (USD)
in 6 rounds
- Latest Funding Round$25M (USD), Post-IPO
Jun 2023
- InvestorsAbbVie
& 24 more
- Employee Count147
Products & Services of Caribou Biosciences
Caribou Biosciences offers a comprehensive portfolio of products and services, including chRDNA Technology and CAR-T Cell Therapies.
Enables precise CRISPR-based editing for gene knockout and insertion.
Develops off-the-shelf treatments for hematologic malignancies and diseases.
Funding Insights of Caribou Biosciences
Caribou Biosciences has successfully raised a total of $156.55M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $156.55M
- Total Rounds 6
- Last Round Post-IPO β $25M
- First Round $158,902
(May 2013)
- Investors Count 25
All 6 funding rounds of Caribou Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $25M | Post-IPO | β | β | |
| Mar 2021 | $115M | Series C | β | Farallon Capital Management, Ridgeback Capital Management | |
| May 2016 | $30M | Series B | β | Anterra Capital, Heritage Group | |
| Mar 2015 | $11.55M | Series A | β | β | |
| Jul 2013 | $150,000 | Grant | β | β | |
| May 2013 | $158,902 | Grant | β | β |
25 investors in total: 25 institutional.
Investors in Caribou Biosciences
Caribou Biosciences has secured backing from 25 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Pfizer and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Ridgeback Capital is focused on healthcare and life science investments. | ridgebackcap.com | New York, United States | ||
Early-stage tech and life-sciences firms are funded across the US. | maverickventures.com | San Francisco, United States | ||
Healthcare startups are funded by this corporate-backed venture capital entity. | lifesciventure.com | New York, United States | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital firm focused on multiple sectors | Dallas, United States | |||
Private equity investments are directed toward the healthcare sector. | avego.com | Alpharetta, United States | ||
Aliment Capital is focused on sustainable food system investments. | alimentcap.com | Los Angeles, United States | ||
Tech focused growth stage VC firm investing in Europe & North America | 2012 | anterracapital.com | Amsterdam, Netherlands |
Investor details for Caribou Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Caribou Biosciences
65 people are tracked at Caribou Biosciences (36 in leadership, 15 in board & advisors, 14 in team); the tracked headcount is 147.
| Name | Role | Group |
|---|---|---|
Jennifer Doudna | Co-Founder | Leadership |
James Berger | Co-Founder | Leadership |
Martin Jinek | Co-Founder | Leadership |
Ruhi Khan | Chief Business Officer | Leadership |
Maryam Sorkhabi | Sr. Director, External Manufacturing Operations | Leadership |
Barbara Mcclung | Chief Legal Officer & Corporate Secretary | Leadership |
Sri Ryali | Chief Financial Officer | Leadership |
Rodolfo Gonzalez | Executive Director, Stem Cell Therapeutics | Leadership |
Chris Holland | Head Of Biometrics | Leadership |
Eddie Ruelas | Director Of IT Applications | Leadership |
Garima Baloria | Director, Regulatory Affairs CMC | Leadership |
Karen Lyle | Senior Director | Leadership |
Madison Kuchta | Director Of Financial Planning And Analysis | Leadership |
Elaine Alambra | VP, Regulatory Affairs & Quality Assurance | Leadership |
Cindy Hayashi | VP, HR | Leadership |
Alexandra Lied | Associate Director Of Program Management | Leadership |
Eric Stawiski | Vice President Of Bioinformatics | Leadership |
Ryan Fischesser | VP, Finance & Controller | Leadership |
Justin Skoble | VP, Technical Operations | Leadership |
Elizabeth Garner | Executive Director Of T Cell Therapeutics And Translational Sciences Laboratory | Leadership |
45 more people are available in the full profile.
Complete people profiles for Caribou Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Caribou Biosciences
Caribou Biosciences is a publicly listed company on the NASDAQ with ticker symbol CRBU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Jul 2021
- Listed onNASDAQ: CRBU
- Listed entityCaribou Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS1420381089
- Share price$0.47 (-5.41% on the day) · 2026-10-13
- Market capitalisation$50.4M
- EPS (diluted, trailing year)$-1.08
- Volume (last session)4,546,001
Financials of Caribou Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $11.2M | -$148.1M | -$132.6M |
| 2024 | $10.0M | -$149.1M | -$162.7M |
| 2023 | $34.5M | -$102.1M | -$112.5M |
| 2022 | $13.8M | -$99.4M | -$102.8M |
| 2021 | $9.6M | -$66.9M | -$66.0M |
Detailed financial statements for Caribou Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Caribou Biosciences
4 dated milestones of Caribou Biosciences across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Caribou Biosciences is founded.
- Funding First funding round of $159K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
Competitors of Caribou Biosciences
Caribou Biosciences has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Caribou Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Caribou Biosciences
The website of Caribou Biosciences (cariboubio.com) receives about 10.3K visits a month.
- Monthly visits10.3K
▼ 25.9% vs previous month
Websites whose visitors overlap most with Caribou Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| andelynbio.com | 100% | 7.1K | #2,697,524 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Caribou Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Caribou Biosciences
Complete news archive for Caribou Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caribou Biosciences
Caribou Biosciences was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Caribou Biosciences is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Caribou Biosciences is a funded company, having raised a total of $156.55M across 6 funding rounds to date. The company's 1st funding round was a Grant of $158.9K, raised on May 2013.
Caribou Biosciences has 147 employees.
Annual revenue of Caribou Biosciences is $11.16M as on Dec 31, 2025.
Caribou Biosciences was founded in 2011 in Berkeley, United States, within the biotechnology sector. Cellular engineering and analysis solutions are developed based on CRISPR-Cas9 biology. These tools are applied across therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. CAR-T cell therapies for non-Hodgkin lymphoma and myeloid leukemia have been created, as have iPSC-derived CAR-NK therapies targeting solid tumors. Operations focus on advancing treatments for hematologic and oncologic conditions.
Caribou Biosciences's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Caribou Biosciences offers chRDNA Technology and CAR-T Cell Therapies.
Yes, Caribou Biosciences is publicly traded on NASDAQ under the ticker symbol CRBU.
Caribou Biosciences has 25 investors. Key investors include AbbVie, Pfizer, Novartis, Janus Henderson Investors, and Farallon Capital Management.
Caribou Biosciences operates through Caribou Biosciences, Inc..
